<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2424">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547299</url>
  </required_header>
  <id_info>
    <org_study_id>MDV3100-07</org_study_id>
    <nct_id>NCT01547299</nct_id>
  </id_info>
  <brief_title>Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer</brief_title>
  <official_title>A Randomized, Open-Label, Phase 2 Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medivation, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if enzalutamide is an effective therapy in
      treating localized prostate cancer prior to prostatectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pathologic complete response rate following triplet therapy (enzalutamide in combination with leuprolide and dutasteride) and enzalutamide alone when administered as neoadjuvant therapy for 6 months prior to prostatectomy in patients with localized prostate cancer. Pathologic complete response is defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen, as evaluated by the site pathologist using standard methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Positive Surgical Margins</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the percentage of patients with positive surgical margins at prostatectomy as assessed by the local and central pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Extracapsular Extension: Local Review</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the percentage of patients with extracapsular extension at prostatectomy as assessed by the local pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Extracapsular Extension: Central Review</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the percentage of patients with extracapsular extension at prostatectomy as assessed by the central pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Positive Seminal Vesicles</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the percentage of patients with positive seminal vesicles at prostatectomy as assessed by the local and central pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Positive Lymph Nodes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the percentage of patients with positive lymph nodes at prostatectomy as assessed by the local and central pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-Specific Antigen (PSA) Nadir</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effects on PSA as measured by the lowest postbaseline PSA value prior to prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate-Specific Antigen (PSA) Nadir</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effects on PSA as measured by the time to the lowest postbaseline PSA value prior to prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Reduction in Prostate-Specific Antigen (PSA)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effects on PSA as measured by the percentage of patients with PSA &lt; 0.2 ng/mL, and a 50% and 90% decrease in PSA value prior to prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Summary Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual domain summary score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Function Subscale Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual function subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Bother Subscale Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual bother subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Domain Summary Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal domain summary score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Function Subscale Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal function subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Bother Subscale Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal bother subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 General Health Domain Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in general health domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Physical Functioning Domain Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in physical functioning domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Role-Emotional Domain Score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in role-emotional domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Mental Component Summary</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in mental component summary is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine pharmacodynamic effects as measured by tissue DHT in prostatectomy specimens following radical prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects: Tissue Testosterone</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine pharmacodynamic effects as measured by tissue testosterone in prostatectomy specimens following radical prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects: Assessment of Apoptosis</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effects of triplet therapy and enzalutamide alone on apoptosis in prostatectomy specimens.
Assessment of apoptosis was not performed due to limited amounts of tissue available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects: Assessment of Mitotic Index</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effects of triplet therapy and enzalutamide alone on mitotic index (rate of cell growth) in prostatectomy specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects: Assessment of Androgen Receptor Signaling</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effects of triplet therapy and enzalutamide alone on androgen receptor signaling in prostatectomy specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Dihydrotestosterone (DHT): Baseline</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Dihydrotestosterone (DHT): 6 Months Postbaseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Dihydrotestosterone (DHT)</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine serum hormone effects as measured by change in DHT values from baseline to the completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Testosterone: Baseline</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Testosterone: 6 Months Postbaseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Testosterone</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine serum hormone effects as measured by change in testosterone at baseline and at completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events (AEs) That Led to Dose Interruption, Dose Reduction, and Study Drug Discontinuation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the number of patients with AEs that led to permanent discontinuation of enzalutamide, temporary interruption of enzalutamide, dose reduction of enzalutamide, or study drug (enzalutamide, leuprolide, or dutasteride) discontinuation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzalutamide 160 mg, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide &amp; Leuprolide &amp; Dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <arm_group_label>Enzalutamide alone</arm_group_label>
    <arm_group_label>Enzalutamide &amp; Leuprolide &amp; Dutasteride</arm_group_label>
    <other_name>MDV3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <arm_group_label>Enzalutamide &amp; Leuprolide &amp; Dutasteride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <arm_group_label>Enzalutamide &amp; Leuprolide &amp; Dutasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to provide informed consent

          -  18 years of age or older

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Must be a candidate for radical prostatectomy and considered surgically resectable

        Exclusion Criteria:

          -  Stage T4 prostate cancer by clinical or radiologic evaluation

          -  Treatment with an investigational agent within 4 weeks prior to randomization

          -  Received therapy for other neoplastic disorders within 5 years

          -  Hypogonadism or severe androgen deficiency
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 21, 2015</lastchanged_date>
  <firstreceived_date>February 27, 2012</firstreceived_date>
  <firstreceived_results_date>March 30, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>prostatectomy</keyword>
  <keyword>neoadjuvant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
          <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
        </group>
        <group group_id="P2">
          <title>Enzalutamide Alone</title>
          <description>Enzalutamide 160 mg, orally, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
          <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
        </group>
        <group group_id="B2">
          <title>Enzalutamide Alone</title>
          <description>Enzalutamide 160 mg, orally, once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="52"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.8" spread="6.95"/>
                <measurement group_id="B2" value="61.4" spread="7.65"/>
                <measurement group_id="B3" value="61.1" spread="7.26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt; 65</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>65 to 74</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;= 75</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="52"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate</title>
        <description>Pathologic complete response rate following triplet therapy (enzalutamide in combination with leuprolide and dutasteride) and enzalutamide alone when administered as neoadjuvant therapy for 6 months prior to prostatectomy in patients with localized prostate cancer. Pathologic complete response is defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen, as evaluated by the site pathologist using standard methods.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the local and central pathologist.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pathologic Complete Response Rate</title>
            <description>Pathologic complete response rate following triplet therapy (enzalutamide in combination with leuprolide and dutasteride) and enzalutamide alone when administered as neoadjuvant therapy for 6 months prior to prostatectomy in patients with localized prostate cancer. Pathologic complete response is defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen, as evaluated by the site pathologist using standard methods.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Local pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.7" lower_limit="1.1" upper_limit="28.0"/>
                  <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="13.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Central pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" lower_limit="0.1" upper_limit="21.9"/>
                  <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="13.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Positive Surgical Margins</title>
        <description>To determine the percentage of patients with positive surgical margins at prostatectomy as assessed by the local and central pathologist.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the local and central pathologist.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Positive Surgical Margins</title>
            <description>To determine the percentage of patients with positive surgical margins at prostatectomy as assessed by the local and central pathologist.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Local pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" lower_limit="0.1" upper_limit="21.9"/>
                  <measurement group_id="O2" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Central pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.7" lower_limit="7.5" upper_limit="43.7"/>
                  <measurement group_id="O2" value="16.0" lower_limit="4.5" upper_limit="36.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Extracapsular Extension: Local Review</title>
        <description>To determine the percentage of patients with extracapsular extension at prostatectomy as assessed by the local pathologist.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the local pathologist.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Extracapsular Extension: Local Review</title>
            <description>To determine the percentage of patients with extracapsular extension at prostatectomy as assessed by the local pathologist.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26.1" lower_limit="10.2" upper_limit="48.4"/>
                  <measurement group_id="O2" value="36.0" lower_limit="18.0" upper_limit="57.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Extracapsular Extension: Central Review</title>
        <description>To determine the percentage of patients with extracapsular extension at prostatectomy as assessed by the central pathologist.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the central pathologist. One patient in the Enzalutamide alone treatment arm was excluded from the analysis because the result reported by the central lab was indeterminate.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Extracapsular Extension: Central Review</title>
            <description>To determine the percentage of patients with extracapsular extension at prostatectomy as assessed by the central pathologist.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56.5" lower_limit="34.5" upper_limit="76.8"/>
                  <measurement group_id="O2" value="70.8" lower_limit="48.9" upper_limit="87.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Positive Seminal Vesicles</title>
        <description>To determine the percentage of patients with positive seminal vesicles at prostatectomy as assessed by the local and central pathologist.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the local and central pathologist.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Positive Seminal Vesicles</title>
            <description>To determine the percentage of patients with positive seminal vesicles at prostatectomy as assessed by the local and central pathologist.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Local pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  <measurement group_id="O2" value="36.0" lower_limit="18.0" upper_limit="57.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Central pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  <measurement group_id="O2" value="36.0" lower_limit="18.0" upper_limit="57.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Positive Lymph Nodes</title>
        <description>To determine the percentage of patients with positive lymph nodes at prostatectomy as assessed by the local and central pathologist.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the local and central pathologist.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Positive Lymph Nodes</title>
            <description>To determine the percentage of patients with positive lymph nodes at prostatectomy as assessed by the local and central pathologist.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Local pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.1" lower_limit="10.2" upper_limit="48.4"/>
                  <measurement group_id="O2" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Central pathologist</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.1" lower_limit="10.2" upper_limit="48.4"/>
                  <measurement group_id="O2" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-Specific Antigen (PSA) Nadir</title>
        <description>To determine the effects on PSA as measured by the lowest postbaseline PSA value prior to prostatectomy.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline PSA and at least one postbaseline PSA.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Prostate-Specific Antigen (PSA) Nadir</title>
            <description>To determine the effects on PSA as measured by the lowest postbaseline PSA value prior to prostatectomy.</description>
            <units>Âµg/L</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.04" lower_limit="0.01" upper_limit="0.53"/>
                  <measurement group_id="O2" value="0.51" lower_limit="0.02" upper_limit="8.80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Prostate-Specific Antigen (PSA) Nadir</title>
        <description>To determine the effects on PSA as measured by the time to the lowest postbaseline PSA value prior to prostatectomy.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline PSA and at least one postbaseline PSA.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Prostate-Specific Antigen (PSA) Nadir</title>
            <description>To determine the effects on PSA as measured by the time to the lowest postbaseline PSA value prior to prostatectomy.</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.09" lower_limit="2.79" upper_limit="6.44"/>
                  <measurement group_id="O2" value="6.01" lower_limit="2.89" upper_limit="6.64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Reduction in Prostate-Specific Antigen (PSA)</title>
        <description>To determine the effects on PSA as measured by the percentage of patients with PSA &lt; 0.2 ng/mL, and a 50% and 90% decrease in PSA value prior to prostatectomy.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline PSA and at least one postbaseline PSA.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Reduction in Prostate-Specific Antigen (PSA)</title>
            <description>To determine the effects on PSA as measured by the percentage of patients with PSA &lt; 0.2 ng/mL, and a 50% and 90% decrease in PSA value prior to prostatectomy.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>PSA &lt; 0.2 ng/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92.0" lower_limit="74.0" upper_limit="99.0"/>
                  <measurement group_id="O2" value="29.6" lower_limit="13.8" upper_limit="50.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>50% decrease in PSA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                  <measurement group_id="O2" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>90% decrease in PSA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0" lower_limit="86.3" upper_limit="100.0"/>
                  <measurement group_id="O2" value="63.0" lower_limit="42.4" upper_limit="80.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Summary Score</title>
        <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual domain summary score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Summary Score</title>
            <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual domain summary score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Function Subscale Score</title>
        <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual function subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Function Subscale Score</title>
            <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual function subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Bother Subscale Score</title>
        <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual bother subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Sexual Bother Subscale Score</title>
            <description>EPIC Sexual Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's sexual function and sexual satisfaction. Best change from baseline category in EPIC sexual bother subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Domain Summary Score</title>
        <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal domain summary score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Domain Summary Score</title>
            <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal domain summary score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Function Subscale Score</title>
        <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal function subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Function Subscale Score</title>
            <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal function subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Bother Subscale Score</title>
        <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal bother subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Expanded Prostate Cancer Index Composite (EPIC) Hormonal Bother Subscale Score</title>
            <description>EPIC Hormonal Domain is an HRQoL instrument that measures the effects of prostate cancer treatment on a patient's hormonal function. Best change from baseline category in EPIC hormonal bother subscale score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 General Health Domain Score</title>
        <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in general health domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 General Health Domain Score</title>
            <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in general health domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Physical Functioning Domain Score</title>
        <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in physical functioning domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Physical Functioning Domain Score</title>
            <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in physical functioning domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Role-Emotional Domain Score</title>
        <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in role-emotional domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Role-Emotional Domain Score</title>
            <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in role-emotional domain score is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Mental Component Summary</title>
        <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in mental component summary is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline and at least one postbaseline score.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Health-Related Quality of Life (HRQoL): The Twelve-Item Short Form Version 2 Mental Component Summary</title>
            <description>The Twelve-Item Short Form Version 2 is an HRQoL instrument that measures general health and well-being across physical and mental components. Best change from baseline category in mental component summary is summarized below. Categories are worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference is defined as one-half the standard deviation of the score of interest at baseline.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)</title>
        <description>To determine pharmacodynamic effects as measured by tissue DHT in prostatectomy specimens following radical prostatectomy.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the central pathologist.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)</title>
            <description>To determine pharmacodynamic effects as measured by tissue DHT in prostatectomy specimens following radical prostatectomy.</description>
            <units>pg/mg</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.03" lower_limit="0.02" upper_limit="0.06"/>
                  <measurement group_id="O2" value="3.12" lower_limit="0.86" upper_limit="8.92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects: Tissue Testosterone</title>
        <description>To determine pharmacodynamic effects as measured by tissue testosterone in prostatectomy specimens following radical prostatectomy.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a prostatectomy sample evaluated by the central pathologist.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pharmacodynamic Effects: Tissue Testosterone</title>
            <description>To determine pharmacodynamic effects as measured by tissue testosterone in prostatectomy specimens following radical prostatectomy.</description>
            <units>pg/mg</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.16" lower_limit="0.04" upper_limit="0.54"/>
                  <measurement group_id="O2" value="0.68" lower_limit="0.16" upper_limit="4.36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects: Assessment of Apoptosis</title>
        <description>To determine the effects of triplet therapy and enzalutamide alone on apoptosis in prostatectomy specimens.
Assessment of apoptosis was not performed due to limited amounts of tissue available.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects: Assessment of Mitotic Index</title>
        <description>To determine the effects of triplet therapy and enzalutamide alone on mitotic index (rate of cell growth) in prostatectomy specimens.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>08/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Effects: Assessment of Androgen Receptor Signaling</title>
        <description>To determine the effects of triplet therapy and enzalutamide alone on androgen receptor signaling in prostatectomy specimens.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>08/2015</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Dihydrotestosterone (DHT): Baseline</title>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline serum DHT result.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Dihydrotestosterone (DHT): Baseline</title>
            <units>ng/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.34" lower_limit="0.08" upper_limit="0.58"/>
                  <measurement group_id="O2" value="0.29" lower_limit="0.16" upper_limit="0.85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Dihydrotestosterone (DHT): 6 Months Postbaseline</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a 6 month postbaseline serum DHT result.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Dihydrotestosterone (DHT): 6 Months Postbaseline</title>
            <units>ng/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.01" lower_limit="0.01" upper_limit="0.04"/>
                  <measurement group_id="O2" value="0.51" lower_limit="0.10" upper_limit="1.10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Dihydrotestosterone (DHT)</title>
        <description>To determine serum hormone effects as measured by change in DHT values from baseline to the completion of therapy.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a serum DHT result at baseline and 6 months postbaseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Serum Dihydrotestosterone (DHT)</title>
            <description>To determine serum hormone effects as measured by change in DHT values from baseline to the completion of therapy.</description>
            <units>ng/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.33" lower_limit="-0.57" upper_limit="-0.07"/>
                  <measurement group_id="O2" value="0.25" lower_limit="-0.16" upper_limit="0.71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Testosterone: Baseline</title>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a baseline serum testosterone result.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Testosterone: Baseline</title>
            <units>ng/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.10" lower_limit="0.77" upper_limit="6.77"/>
                  <measurement group_id="O2" value="3.69" lower_limit="2.00" upper_limit="7.91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Testosterone: 6 Months Postbaseline</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a 6 month postbaseline serum testosterone result.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Testosterone: 6 Months Postbaseline</title>
            <units>ng/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.12" lower_limit="0.05" upper_limit="0.29"/>
                  <measurement group_id="O2" value="9.76" lower_limit="1.99" upper_limit="16.63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Testosterone</title>
        <description>To determine serum hormone effects as measured by change in testosterone at baseline and at completion of therapy.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomly assigned to study treatment (intent-to-treat population) with a serum testosterone result at baseline and 6 months postbaseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Serum Testosterone</title>
            <description>To determine serum hormone effects as measured by change in testosterone at baseline and at completion of therapy.</description>
            <units>ng/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-4.00" lower_limit="-6.67" upper_limit="-0.67"/>
                  <measurement group_id="O2" value="5.74" lower_limit="-1.94" upper_limit="12.29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events (AEs) That Led to Dose Interruption, Dose Reduction, and Study Drug Discontinuation</title>
        <description>To assess the number of patients with AEs that led to permanent discontinuation of enzalutamide, temporary interruption of enzalutamide, dose reduction of enzalutamide, or study drug (enzalutamide, leuprolide, or dutasteride) discontinuation.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All patients who received at least one partial dose of enzalutamide.</population>
        <group_list>
          <group group_id="O1">
            <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
            <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Enzalutamide Alone</title>
            <description>Enzalutamide 160 mg, orally, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With Adverse Events (AEs) That Led to Dose Interruption, Dose Reduction, and Study Drug Discontinuation</title>
            <description>To assess the number of patients with AEs that led to permanent discontinuation of enzalutamide, temporary interruption of enzalutamide, dose reduction of enzalutamide, or study drug (enzalutamide, leuprolide, or dutasteride) discontinuation.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Permanent Discontinuation of Enzalutamide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temporary Interruption of Enzalutamide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dose Reduction of Enzalutamide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Study Drug Discontinuation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enzalutamide &amp; Leuprolide &amp; Dutasteride</title>
          <description>Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily</description>
        </group>
        <group group_id="E2">
          <title>Enzalutamide Alone</title>
          <description>Enzalutamide 160 mg, orally, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oestradiol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Restless leg syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI agrees not to independently publish the results before the publication of the multi-center PI paper. Sponsor shall review and comment 30 days prior to submission or disclosure. If publication or disclosure contains Sponsor Confidential Information, other than study data, PI agrees to remove Confidential Information from publication or disclosure. Sponsor may request that PI delay such publication for an additional 60 days to protect the patentability of any invention described.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Novotny, MD, Sr. Director, Clinical Development</name_or_title>
      <organization>Medivation, Inc.</organization>
      <phone>415- 983-3066</phone>
      <email>william.novotny@medivation.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
